Agustin Melian, MD


Agustin Melian, MD

Chief Medical Officer & Head of Global Medical Sciences

Dr. Melian joined AlloVir from Alexion Pharmaceuticals where he served as an SVP in both Global Clinical Development and Medical Sciences. While there the company achieved record timelines across clinical development including Ultomiris  (a >500 patients rare disease development program fully executed from IND to filing in <2.5 years), 3 successful BLAs (Strensiq, Kanuma and Ultomiris), sBLAs submitted for Soliris in Myasthenia Gravis and Neuromyelitis Optica Spectrum Disorder (NMOSD), a NORD Rare impact award, A Prix Galien (Germany), 2 Breakthrough Designations, 2 Pediatric Vouchers, regulatory approvals in Paroxysmal Nocturnal Hemoglobinuria, Hypophosphatasia, Lysosomal Acid Lipase Deficiency and Myasthenia Gravis, business acquisitions of  Syntimmune, and Wilson Therapeutics,  collaborative research agreements with Caleum, Dicerna, Zealand and  Affibody, and a quadrupling of the number of products on the market .

Dr. Melian also spent 13 years at Merck where he played roles of across clinical development including Product Development Team Leader, Head of Emerging Markets Clinical Development, Head of Japanese Clinical Development, and Head of the Global Medical Organization.

Prior to joining industry, Dr. Melian practiced Medicine and conducted Basic Immunology Research at The Brigham and Women’s Hospital in Boston. He graduated cum laude with degrees in Molecular Biophysics and Biochemistry and in Medicine from Yale University.  He also has a background in DNA transcription and repair.